Magnesium and C-reactive protein in heart failure: an anti-inflammatory effect of magnesium administration?
- 338 Downloads
Little is known about the relationship between serum magnesium (Mg) and C-reactive protein (CRP) in heart failure (HF).
Aim of the study
To investigate the relationship, if any, between serum Mg and CRP in HF patients and, concomitantly, to test a hypothesis that Mg supplementation might affect serum CRP levels.
Serum Mg and CRP were evaluated in 68 patients with chronic systolic HF leading to hospital admission and 65 patients requiring hospitalization for other causes. Following 5 weeks, serum Mg, CRP and intracellular Mg were reevaluated in 17 HF patients after administration of oral Mg citrate 300 mg/day (group A), and 18 untreated HF patients (group B). In order to obtain Gaussian distribution, logarithmic transformation of CRP was performed.
Inverse correlation was found between serum Mg and log CRP (r = −0.28, P = 0.002). Compared to controls, patients with HF demonstrated higher baseline CRP levels, independent of coexisting conditions, and lower serum Mg values. Following Mg treatment, log CRP decreased from 1.4 ± 0.4 to 0.8 ± 0.3 in group A (P < 0.001). No significant changes in log CRP were demonstrable in group B. Serum Mg (mmol/l) rose significantly in group A (0.74 ± 0.04–0.88 ± 0.08, P < 0.001), and to a lesser extent in group B (0.82 ± 0.08–0.88 ± 0.08, P = 0.04). Intracellular Mg significantly increased only in Mg-treated group A (P = 0.01).
Oral Mg supplementation to HF patients significantly attenuates blood levels of CRP, a biomarker of inflammation. Targeting the inflammatory cascade by Mg administration might prove a useful tool for improving the prognosis in HF.
Keywordsheart failure magnesium CRP inflammation
- 4.Sueta CA, Patterson JH, Adams KF Jr (1995) Antiarrhythmic action of pharmacologic administration of magnesium in heart failure: a critical review of new data. Magn Res 8:389–401Google Scholar
- 15.Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer DB, Levy D, Wilson PW, D’Agostino RB (2003) Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 107:1486–1491CrossRefPubMedGoogle Scholar
- 24.Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Jacobs AK, Hiratzka LF, Russell RO, Smith SC Jr (2001) ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. Circulation 104:2996–3007PubMedGoogle Scholar
- 27.Dixon WJ (Chief ed) (1993) BMDP statistical software. University of California Press, Los-AngelesGoogle Scholar
- 34.Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT (2003) Randomized, double-blind, placebo- controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of ATTACH trial. Circulation 107:3133–3140CrossRefPubMedGoogle Scholar
- 35.Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T (2004) Targeted anticytokine therapy in patients with chronic heart failure: results of RENEWAL trial. Circulation 109:1594–1602CrossRefPubMedGoogle Scholar
- 39.Spasov AA, Temkin ES, Ostrovskii OV, Kalinina NV, Gerchikov LV, Mikhal’chenko VF, Demina LV (1999) The experimental and clinical validation of the use of a polikatan preparation in periodontal diseases. Stomatologiia (Mosk) 78:16–19Google Scholar